Figure 6.

Protection against tumor development by curdlan treatment. (A) (NODxB6)F1.RET⁺ transgenic mice (6–7 weeks of age) were injected intraperitoneally twice with curdlan (100 µg/g of body weight, n = 12) or with PBS (n = 9) with a one-week interval and were monitored weekly for tumor progression. The data are pooled from two experiments conducted at an interval of 6 mo. The mean tumor score and its standard deviation are shown at each timepoint. The difference of tumor scores between both groups was tested using a linear model with mixed effects. (B) Reduction of CD4⁺Foxp3⁺ T cells in tumors of curdlan-treated mice.